Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease's progression - were always a long-shot, although they had offered the drugmaker a potential ... ...

Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide. The oral medication failed to pare back progression in the memory-loss disease. NVO has been on a steep, downward trajectory since topping out at a record high of $148.15 in June of 2024. The 120-day moving average has loomed as overhead resistance, capping several breakout attempts this past year ...

编辑：雨林 11月24日，诺和诺德表示，该公司的一项口服司美格鲁肽用于治疗阿尔茨海默病的临床试验失败， 未能延缓疾病进展。诺和诺德盘前股价大跌超10%。 ...

Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to ... ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

Shares of Danish pharma major Novo Nordisk's plummeted a record 12.4% on 24 November — it's lowest since July 2021, after the company's popular weight-loss pill Ozempic failed trials for Alzheimer's treatment, Bloomberg reported.Novo Nordisk has discontinued its planned one-year extension for the pair of studies that were testing the drug's effectiveness in slowing the progression of Alzheimer's disease, it added.The two trials, with 3,500 participants with mild Alzheimer’s disease, had a 75% probability of ...

诺和诺德司美格鲁肽临床试验结果 - 诺和诺德宣布其药物司美格鲁肽（semaglutide）未能延缓阿尔茨海默症的疾病进展 [1] 公司股价市场反应 - 诺和诺德股价因该负面临床试验结果而承压 [1] - 礼来（Eli Lilly）与渤健（Biogen）公司股价因相对预期提升而出现上涨 [1]

Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.The company had been testing whether a key ingredient in the drugs could slow progression of the brain disorder. Novo Nordisk, which began the trials two years ago, had always treated the study as an outside bet but one which had the potential to land big rewards, if successful, as earnings from its core diabetes ...

Key Takeaways Novo Nordisk unveiled limited-time $199 pricing for new Wegovy and Ozempic self-pay patients.Pricing shifts follow an agreement to expand U.S. access and move patients toward FDA-approved treatments.Novo Nordisk seeks to regain share from Lilly as compounded products pressure demand and guidance cuts.Last week, Novo Nordisk (NVO) announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per m ...

诺和诺德周一表示，其备受关注的口服版本司美格鲁肽在阿尔茨海默病方面的最新试验未能减缓这一神经退行性疾病的进展，这一结 果对这家减重药物巨头构成打击，并导致股价下滑。公司此前将该研究称为"彩票式机会"，强调结果存在高度不确定性，同时试验旨 在评估该药物能否减少患者的认知衰退。 此次失利终结了诺和诺德希望借阿尔茨海默病开辟GLP-1药物新市场的可能性，尤其是在其肥胖和糖尿病核心业务竞争不断加剧的背 景下。诺和诺德股东Storebrand资产管理公司投资经理Erik Berg-Johnsen对路透表示，这一失败很可能"为公司在阿尔茨海默领域的探 索钉上最后一颗钉子"。他指出，试验在原计划持续三年的情况下提前在两年时停止，表明司美格鲁肽几乎未能提供任何减缓病情进展 的效果。 整理 | GLP1减重宝典内容团队 这项试验备受关注，市场希望借此判断广泛用于糖尿病和体重管理的GLP-1药物是否可能对阿尔茨海默病产生影响。此次研究对象为 Rybelsus，这是一种仅获批用于2型糖尿病的口服药物，与诺和诺德的Ozempic和Wegovy含有相同活性成分。 公司此前将阿尔茨海默病项目称为"彩票式机会"，凸显其高潜力与高不确定性并 ...